Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Alaunos Therapeutics ( (TCRT) ) just unveiled an announcement.
On May 19, 2025, Alaunos Therapeutics entered into an equity purchase agreement with Mast Hill Fund, allowing for the sale of up to $25 million in common stock. This agreement provides Alaunos with financial flexibility to manage its operations and funding needs over a 24-month period, with Mast Hill obligated to purchase shares as directed by Alaunos, subject to certain conditions.
Spark’s Take on TCRT Stock
According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.
Alaunos Therapeutics’ overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.
To see Spark’s full report on TCRT stock, click here.
More about Alaunos Therapeutics
Alaunos Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies. The company is engaged in the research and development of treatments for cancer and other serious diseases.
Average Trading Volume: 480,930
Technical Sentiment Signal: Sell
Current Market Cap: $4.33M
See more insights into TCRT stock on TipRanks’ Stock Analysis page.